摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

chlorido[3-(oxo-κO)-2-methyl-4-pyronato-κO4](η6-p-isopropyltoluene)ruthenium(II) | 937035-54-6

中文名称
——
中文别名
——
英文名称
chlorido[3-(oxo-κO)-2-methyl-4-pyronato-κO4](η6-p-isopropyltoluene)ruthenium(II)
英文别名
chlorido[2-methyl-3-(oxo-κO)-pyran-4(1H)-onato-κO4](eta.6-p-cymene)ruthenium(II);chlorido[3-hydroxy-2-methylpyrane-4(1H)-one](η6-p-cymene)ruthenium(II);chlorido[3-hydroxy-2-methylpyrane-4(1H)-one](cym)ruthenium(II);(η6-p-isopropyltoluene)RuCl(maltol(-H));[RuCl(η6-p-cymene)(C5H2O(O)(O)Me)]
chlorido[3-(oxo-κO)-2-methyl-4-pyronato-κO4](η6-p-isopropyltoluene)ruthenium(II)化学式
CAS
937035-54-6
化学式
C16H19ClO3Ru
mdl
——
分子量
395.848
InChiKey
SBXAMHUQWLDODL-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    None
  • 重原子数:
    None
  • 可旋转键数:
    None
  • 环数:
    None
  • sp3杂化的碳原子比例:
    None
  • 拓扑面积:
    None
  • 氢给体数:
    None
  • 氢受体数:
    None

反应信息

  • 作为反应物:
    描述:
    chlorido[3-(oxo-κO)-2-methyl-4-pyronato-κO4](η6-p-isopropyltoluene)ruthenium(II) 为溶剂, 生成 [{(η6-p-cymene)Ru}22-OH)3]+
    参考文献:
    名称:
    From Pyrone to Thiopyrone Ligands−Rendering Maltol-Derived Ruthenium(II)−Arene Complexes That Are Anticancer Active in Vitro
    摘要:
    Ru(II)-arene complexes with pyrone-derived ligands are rendered active against cancer cells by replacement of the coordinated O,O donor with an S,O donor. The different stabilities of these systems may explain the observed influence of the donor atoms on the anticancer activity in vitro.
    DOI:
    10.1021/om900483t
  • 作为产物:
    描述:
    麦芽醇 、 [ruthenium(II)(η6-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]2 在 sodium methoxide 作用下, 以 not given 为溶剂, 生成 chlorido[3-(oxo-κO)-2-methyl-4-pyronato-κO4](η6-p-isopropyltoluene)ruthenium(II)
    参考文献:
    名称:
    From Pyrone to Thiopyrone Ligands−Rendering Maltol-Derived Ruthenium(II)−Arene Complexes That Are Anticancer Active in Vitro
    摘要:
    Ru(II)-arene complexes with pyrone-derived ligands are rendered active against cancer cells by replacement of the coordinated O,O donor with an S,O donor. The different stabilities of these systems may explain the observed influence of the donor atoms on the anticancer activity in vitro.
    DOI:
    10.1021/om900483t
点击查看最新优质反应信息

文献信息

  • Cationic Ru(η <sup>6</sup> ‐ <i>p</i> ‐cymene) Complexes of 3‐Hydroxy‐4‐pyr(id)ones – Lipophilic Triphenylphosphine as Co‐Ligand Is Key to Highly Stable and Cytotoxic Anticancer Agents
    作者:Shahida Parveen、Muhammad Hanif、Sanam Movassaghi、Matthew P. Sullivan、Mario Kubanik、Muhammad Ashraf Shaheen、Tilo Söhnel、Stephen M. F. Jamieson、Christian G. Hartinger
    DOI:10.1002/ejic.201601163
    日期:2017.3.27
    Ru(arene)(3-hydroxy-4(1H)-pyr(id)one)Cl complexes are known to be converted in aqueous solution to trishydroxido-bridged dinuclear Ru(arene) compounds. In an attempt to obtain anticancer Ru(arene) complexes of 3-hydroxy-4(1H)-pyr(id)one ligands that are stable in aqueous solution, triphenylphosphine (PPh3) and 1,3,5-triaza-7-phoshatricyclo[3.3.1.1]decane (pta) were introduced as co-ligands instead
    已知 Ru(芳烃)(3-羟基-4(1H)-pyr(id)one)Cl 配合物在溶液中转化为三羟基桥连的双核 Ru(芳烃) 化合物。为了获得在溶液中稳定的 3-羟基-4(1H)-(id)酮配体的抗癌 Ru(芳烃)配合物,三苯基膦 (PPh3) 和 1,3,5-triaza-7-phoshatricyclo [3.3.1.1]癸烷 (pta) 作为共配体而不是配体引入。这导致了一系列使用标准方法和 X 射线衍射分析表征的阳离子配合物。发现 pta 复合物在溶液中高度稳定长达 120 小时。虽然它们在 l-组酸存在下不反应,但 l-半胱酸诱导 3-羟基-4(1H)-pyr(id)one 配体从 Ru 中心裂解。
查看更多